Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04442126 · OUTCOME

Determination of Phase 2 Dose of NM21-1480

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors · Source last updated 2025-05-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
mg
Interval / dispersion
Not reported
Time frame
From baseline to up to 12 weeks post last dose, up to 48 weeks.

What was measured

To determine the recommended Phase 2 dose of NM21-1480 for Part B of the study

Groups in this outcome

Part A Dose Level 7 NM21-1480-Q2W 800mg

Part A Dose Level 7 NM21-1480-Q2W 800mg

Part A2 NM21-1480-Q2W 1400mg

Part A2 NM21-1480-Q2W 1400mg

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part A Dose Level 7 NM21-1480-Q2W 800mg26
Part A2 NM21-1480-Q2W 1400mg5

Reported measurements

Source class 1
Values in mg · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part A Dose Level 7 NM21-1480-Q2W 800mg800Not reportedNot reportedNot reportedNot reported
Part A2 NM21-1480-Q2W 1400mg800Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        800
      2. group Id
        OG001
        value
        800
denoms
  1. counts
    1. group Id
      OG000
      value
      26
    2. group Id
      OG001
      value
      5
    units
    Participants
description
To determine the recommended Phase 2 dose of NM21-1480 for Part B of the study
groups
  1. description
    Part A Dose Level 7 NM21-1480-Q2W 800mg
    id
    OG000
    title
    Part A Dose Level 7 NM21-1480-Q2W 800mg
  2. description
    Part A2 NM21-1480-Q2W 1400mg
    id
    OG001
    title
    Part A2 NM21-1480-Q2W 1400mg
param Type
NUMBER
reporting Status
POSTED
time Frame
From baseline to up to 12 weeks post last dose, up to 48 weeks.
title
Determination of Phase 2 Dose of NM21-1480
type
PRIMARY
unit Of Measure
mg

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice